ArticleMolecular and cellular pharmacology2011
Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes.
Article in Molecular and cellular pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- The Antimicrobial Peptide γ-Thionin from Habanero Chile (Molecules (Basel, Switzerland) · 2023Article
- Epigenetic Deregulation of Apoptosis in Cancers.Cancers · 2021Review
- Histone Lysine Methylation and Long Non-Coding RNA: The New Target Players in Skeletal Muscle Cell Regeneration.Frontiers in cell and developmental biology · 2021Review
- Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.Molecular carcinogenesis · 2020Article
- Inhibition of histone deacetylation rescues phenotype in a mouse model of Birk-Barel intellectual disability syndrome.Nature communications · 2020Article
- The timeline of epigenetic drug discovery: from reality to dreams.Clinical epigenetics · 2019Review
- The Epigenetics of Aging in Invertebrates.International journal of molecular sciences · 2019Review
- Clinical epigenetics: seizing opportunities for translation.Nature reviews. Genetics · 2019Review
- Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- A ketogenic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Sexually Dimorphic Epigenetic Regulation of Brain-Derived Neurotrophic Factor in Fetal Brain in the Valproic Acid Model of Autism Spectrum Disorder.Developmental neuroscience · 2017Article
- An epigenetic switch regulates de novo DNA methylation at a subset of pluripotency gene enhancers during embryonic stem cell differentiation.Nucleic acids research · 2016Article
- Epigenetic Regulation of Cytosolic Phospholipase A2 in SH-SY5Y Human Neuroblastoma Cells.Molecular neurobiology · 2016Article
- Article
- The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.BMC cancer · 2015Article
- Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.Cell & bioscience · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
A recent study reports that histone deacetylase (HDAC) inhibitors, AR42 and MS- 275, upregulated H3K4 methylation marks in prostate cancer cells, leading to transcriptional activation of genes including those associated with roles in tumor suppression and cell differentiation (1). Evidence suggests that the crosstalk between histone deacetylation and histone H3K4 methylation is attributable to the ability of these HDAC inhibitors to repress the JARID1 family of histone H3 lysine 4 demethylases (H3K4DMs), including RBP2, PLU-1, SMCX, and LSD1, through the downregulation of Sp1 expression. This demonstrates the complexity of the functional roles of HDACs in the regulation of histone modifications as well as the activation of epigenetically silenced gene expression. Equally important is the ability of HDAC inhibitors to transcriptionally suppress H3K4DM gene expression which has therapeutic implications, in that several H3K4DMs such as LSD1 and PLU-1 have been implicated in the pathogenesis of many types of malignancies.
Identifiers
22468166PMC3315589W2108009014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.